Table 1.
Drug transporter-related miRNAs and their effects on the susceptibility of cancer cells to anti-cancer treatments.
| MiRNAs | Target Gene(s) | Cancer Type | Effect of MiRNAs | Ref. |
|---|---|---|---|---|
| miR-20a-5p | MAPK1 | Breast cancer | Over-expression of miR-20a-5p increases the overall cytotoxicity of several agents, such as vinorelbine, doxorubicin, and paclitaxel | [44] |
| miR-27-3p | FZD7 | Hepatocellular carcinoma | Over-expression of miR-27-3p enhances the sensitivity of multidrug-resistant cells to 5-fluorouracil | [33] |
| miR-122-5p | CTNNB1 | Hepatocellular carcinoma | Up-regulation of miR-122-5p raises the anti-cancer effect of oxaliplatin | [34] |
| miR-129-5p | ABCB1 | Gastric cancer | Up-regulation of miR-129-5p heightens cisplatin-induced cell death and caspase activation | [17] |
| miR-133a-3p | ABCC1 | Hepatocellular carcinoma | Over-expression of miR-133a-3p leads to elevated cytotoxicity of doxorubicin | [23] |
| miR-148a-3p miR-148b-3p miR-152-3p |
SPIN1 | Breast cancer | Over-expression of these miRNAs re-sensitizes the drug-resistant cells to doxorubicin | [45] |
| miR-199a-3p | MTOR | Cholangiocarcinoma | Reconstitution of miR-199a-3p increases growth inhibition rate and apoptosis induced by cisplatin | [39] |
| miR-210-3p | ABCC5 | Pancreatic cancer | Elevated miR-210-3p levels improve the overall cytotoxicity of gemcitabine | [26] |
| miR-218-5p | PRKCE | Gallbladder cancer | Elevated miR-218-5p levels potentiate gemcitabine-mediated cell death and growth inhibition | [38] |
| miR-223-3p | ABCB1 | Hepatocellular carcinoma | Down-regulation of miR-223-3p confers resistance to doxorubicin | [18] |
| miR-326 | ABCC1 | Hepatocellular carcinoma | Over-expression of miR-326 leads to elevated cytotoxicity of doxorubicin | [23] |
| miR-328-3p | ABCG2 | Breast cancer | Over-expression of miR-328-3p augments the sensitivity of drug-resistant cells to mitoxantrone | [29] |
| miR-491-3p | ABCB1, SP3 | Hepatocellular carcinoma | Down-regulation of miR-491-3p decreases the sensitivity to doxorubicin and vinblastin | [19] |
| miR-495-3p | ABCB1, UBE2C | Ovarian cancer, Gastric cancer, Lung cancer | Up-regulation of miR-495-3p re-sensitizes drug-resistant ovarian and gastric cancer cells to doxorubicin/paclitaxel combination, and cisplatin resistance is reversed in miR-495-3p over-expressing lung cancer cells | [20,46] |
| miR-506-3p | CTNNB1 | Colorectal cancer | Over-expression of miR-506-3p re-sensitizes drug-resistant cells to oxaliplatin | [35] |
| miR-508-5p | ABCB1, ZNRD1 | Gastric cancer | Down-regulation of miR-508-5p confers resistance to cisplatin, doxorubicin, vincristine, and 5-fluorouracil | [21] |
| miR-514 | ABCA1, ABCA10, ABCF2 | Ovarian cancer | Up-regulation of miR-514 re-sensitizes drug-resistant cells to cisplatin | [28] |
| miR-595 | SLC19A1, ABCB1 | Acute lymphoblastic leukemia, Ovarian cancer | Over-expression of miR-595 can either decrease or increase the efficacy of methotrexate or cisplatin, respectively | [30,31] |
| miR-1268a | ABCC1 | Glioblastoma | Over-expression of miR-1268a augments temozolomide sensitivity | [24] |